Growth Metrics

Tonix Pharmaceuticals Holding (TNXP) Income towards Parent Company (2023 - 2025)

Historic Income towards Parent Company for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to -$31.8 million.

  • Tonix Pharmaceuticals Holding's Income towards Parent Company fell 10102.29% to -$31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$97.7 million, marking a year-over-year increase of 3109.61%. This contributed to the annual value of -$136.7 million for FY2024, which is 3920.11% down from last year.
  • Latest data reveals that Tonix Pharmaceuticals Holding reported Income towards Parent Company of -$31.8 million as of Q3 2025, which was down 10102.29% from -$27.4 million recorded in Q2 2025.
  • In the past 5 years, Tonix Pharmaceuticals Holding's Income towards Parent Company ranged from a high of -$15.8 million in Q3 2024 and a low of -$77.3 million during Q2 2024
  • Its 3-year average for Income towards Parent Company is -$29.7 million, with a median of -$27.3 million in 2023.
  • Data for Tonix Pharmaceuticals Holding's Income towards Parent Company shows a peak YoY increase of 6462.14% (in 2025) and a maximum YoY decrease of 10102.29% (in 2025) over the last 5 years.
  • Quarter analysis of 3 years shows Tonix Pharmaceuticals Holding's Income towards Parent Company stood at -$27.3 million in 2023, then grew by 17.72% to -$22.5 million in 2024, then crashed by 41.62% to -$31.8 million in 2025.
  • Its Income towards Parent Company stands at -$31.8 million for Q3 2025, versus -$27.4 million for Q2 2025 and -$16.1 million for Q1 2025.